targeting dnan tuberculosis therapy using novel griselimycins
discovery streptomyces-produced streptomycin founded age tuberculosis therapy despite subsequent development curative regimen disease tuberculosis remains worldwide problem emergence multidrug-resistant mycobacterium tuberculosis prioritized need new drugs show new optimized derivatives streptomyces-derived griselimycin highly active m tuberculosis vitro vivo inhibiting dna polymerase sliding clamp dnan discovered resistance griselimycins occurring low frequency associated amplification chromosomal segment containing dnan well ori site results demonstrate griselimycins high translational potential tuberculosis treatment validate dnan antimicrobial target capture process antibiotic pressure-induced gene amplification
